Treatment for Rectal Chlamydia and Gonorrhea
For rectal gonorrhea, treat with ceftriaxone 250 mg intramuscularly as a single dose PLUS azithromycin 1 g orally as a single dose; for rectal chlamydia, doxycycline 100 mg orally twice daily for 7 days is superior to azithromycin and should be the preferred treatment.
Rectal Gonorrhea Treatment
The most recent CDC guidelines recommend combination therapy for all gonococcal infections, including anorectal sites 1. The regimen consists of:
- Ceftriaxone 250 mg IM single dose
- PLUS Azithromycin 1 g orally single dose (preferred over doxycycline due to convenience and lower tetracycline resistance rates)
Rationale for Dual Therapy
The combination approach serves two critical purposes: it addresses the high prevalence of chlamydial coinfection (20-40% in many populations) and theoretically delays the emergence of cephalosporin resistance through dual mechanisms of action 1. Given the historical pattern of fluoroquinolone resistance spreading rapidly among men who have sex with men (MSM), maintaining ceftriaxone effectiveness is paramount 1.
Alternative Regimens
If ceftriaxone is unavailable 1:
- Cefixime 400 mg orally single dose PLUS azithromycin 1 g orally
- Requires test-of-cure in 1 week (cefixime cures only 97.4% of anorectal infections versus 99.1% for ceftriaxone) 2
For severe cephalosporin allergy 1:
- Azithromycin 2 g orally single dose
- Requires test-of-cure in 1 week
Rectal Chlamydia Treatment
Doxycycline is definitively superior to azithromycin for rectal chlamydia. A 2021 randomized controlled trial demonstrated microbiological cure rates of 100% with doxycycline versus 74% with azithromycin at 4 weeks (absolute difference 26%, P<0.001) 3. This represents the highest quality evidence available and should guide treatment decisions.
Recommended Regimen
- Doxycycline 100 mg orally twice daily for 7 days 3
Alternative (Less Effective)
- Azithromycin 1 g orally single dose (only if doxycycline contraindicated or compliance concerns overwhelming) 4
Clinical Impact
Real-world data from Seattle's Sexual Health Clinic showed a 16.9% greater reduction in recurrent/persistent rectal chlamydia cases after switching exclusively to doxycycline in 2016, compared to gonorrhea as a control 5. This demonstrates meaningful population-level benefit.
Critical Management Points
Test-of-Cure Requirements
- Pharyngeal gonorrhea: Always required 6
- Rectal chlamydia treated with azithromycin: Required 6
- Rectal chlamydia treated with doxycycline: Not routinely required (given 100% cure rate) 3
- Rectal gonorrhea treated with ceftriaxone + azithromycin: Not required unless symptoms persist 2
Sexual Abstinence
Patients must abstain from sexual intercourse for 7 days after single-dose therapy or until completion of 7-day regimens AND until all partners are treated 2. This prevents reinfection, which is the most common cause of positive repeat testing rather than treatment failure 2.
Partner Management
All sexual partners within 60 days before symptom onset or diagnosis require evaluation and treatment for both gonorrhea and chlamydia, regardless of which infection the index patient had 2.
Common Pitfalls
False Positive Results: Approximately 19% of patients in the doxycycline trial had negative repeat NAATs at enrollment despite positive clinical tests 3. This highlights the importance of confirmatory testing when feasible, though treatment should not be delayed.
Geographic Resistance Patterns: While older guidelines mentioned quinolone options 4, 2, these are now obsolete due to widespread fluoroquinolone resistance. Never use quinolones for gonorrhea treatment 1.
Pregnancy Considerations: Pregnant patients cannot receive doxycycline or quinolones. Use ceftriaxone for gonorrhea and erythromycin or amoxicillin for chlamydia 4, 2.
Treatment Failure: If symptoms persist after recommended therapy, obtain culture with antimicrobial susceptibility testing and consult infectious disease specialists 1. Report suspected treatment failures to local health departments 2.